Induction of cytotoxicity against autologous tumour cells by interleukin-12: Evidence for intrinsic anti-tumor immune capacity in curatively resected gastrointestinal tumour patients

Cancer Immunology, Immunotherapy

Volumn 51, Issue 9, 2002, Pages 505-512

  Ströhlein, Michael Alfred ^a   Grützner, Klaus Uwe ^a   Schildberg, Friedrich Wilhelm ^a   Heiss, Markus Maria ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Autologous anti tumor capacity; Curative tumour surgery; Disseminated tumour cells; Interleukin 12; Tumour immunology

Indexed keywords

ANTIBODY; INTERLEUKIN 12; INTERLEUKIN 2;

ADULT; AGED; ARTICLE; CANCER SURGERY; CLINICAL ARTICLE; COLORECTAL CARCINOMA; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; FEMALE; FLUORESCENCE ANALYSIS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MONONUCLEAR CELL; NATURAL KILLER CELL; PRIORITY JOURNAL; SOLID TUMOR; STOMACH CARCINOMA; T LYMPHOCYTE; TARGET CELL; TUMOR IMMUNITY; TUMOR IMMUNOLOGY; TUMOR RECURRENCE;

ADJUVANTS, IMMUNOLOGIC; AGED; AREA UNDER CURVE; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-12; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; STOMACH NEOPLASMS; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0036390031     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-002-0310-6     Document Type: Article

References (33)

1. Bertagnolli MM, Lin BY, Young D, Herrmann SH (1992) IL-12 augments antigen-dependent proliferation of activated T lymphocytes. J Immunol 149:3778
2. + CTL responses in vitro. J Clin Invest 98:715
3. Boon T. 1993. Tumor antigens recognized by cytolytic T lymphocytes: present perspectives for specific immunotherapy. Int J Cancer 54:177
4. Cella M, Scheidegger D, Palmer-Lehmann K, Lane P, Lanzavecchia A, Alber G (1996) Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 184:747
5. Chen YM, Yang WK, Ting CC, Tsai WY, Yang DM, Whang-Peng J, Perng RP (1997) Cross-regulation by IL-10 and IL-2/IL-12 of the helper T cells and the cytolytic activity of lymphocytes from malignant effusions of lung cancer patients. Chest 112:966
6. Clerici M, Lucey DR, Berzofsky JA, Pinto LA, Wynn TA, Blatt SP, Dolan MJ, Hendrix CW, Wolf SF, Shearer GM (1993) Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro. Science 262:1721
7. Cote RJ, Rosen PP, Lesser ML, Old LJ, Osborne MP (1991) Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. J Clin Oncol 9:1749
8. Dye JF, Somers SS, Guillou PJ (1991). Simplified quantitation of cytotoxicity by integration of specific lysis against effector cell concentration at a constant target cell concentration and measuring the area under the curve. J Immunol Methods 138:1
9. Gately MK, Desai BB, Wolitzky AG, Quinn PM, Dwyer CM, Podlaski FJ, Familletti PC, Sinigaglia F, Chizonnite R, Gubler U (1991) Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). J Immunol 147:874
10. Gately MK, Wolitzky AG, Quinn PM, Chizzonite R (1992) Regulation of human cytolytic lymphocyte responses by interleukin-12. Cell Immunol 143:127
11. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA (1982) Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin-2-activated autologous human peripheral blood lymphocytes. J Exp Med 155:1823
12. Grohmann U, Bianchi R, Belladonna ML, Vacca C, Silla S, Ayroldi E, Fioretti MC, Puccetti P (1999) IL-12 acts selectively on CD8a. J Immunol 163:3100
13. Grufman P, Karre K. 2000. Innate and adaptive immunity to tumors: IL-12 is required for optimal responses. Eur J Immunol 30:1088
14. Heiss MM, Allgayer H, Grützner KU, Babic R, Jauch KW, Schildberg FW (1997) Clinical value of extended biologic staging by bone marrow micrometastases and tumor-associated proteases in gastric cancer. Ann Surg 226:736
15. Heiss MM, Allgayer H, Grützner KU, Funke I, Babic R, Jauch KW, Schildberg FW (1995) Individual development and uPA-receptor expression of disseminated tumour cells in bone marrow: a reference to early systemic disease in solid cancer. Nat Med 1:1035
16. Heiss MM, Allgayer H, Grützner KU, Tarabichi A, Babic R, Mempel W, Jauch KW, Schildberg FW (1997) Prognostic influence of blood transfusion on minimal residual disease in resected gastric cancer patients. Anticancer Res 17:2657
17. Hendrzak JA, Brunda MJ (1995) Interleukin-12. Biologic activity, therapeutic utility, and role in disease. Lab Invest 72:619
18. Itoh K, Platsoucas CD, Balch CM (1988) Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin-2 and autologous tumor cells, and involvement of the T cell receptor. J Exp Med 168:1419
19. Jauch KW, Heiss MM, Grützner U, Funke I, Pantel K, Babic R, Eissner HJ, Riethmüller G, Schildberg FW (1996) Prognostic significance of bone marrow micrometastases in patients with gastric cancer. J Clin Oncol 14:1810
20. Kolber MA, Quinones RR, Gress RE, Henkart PA (1988) Measurement of cytotoxicity by target cell release and retention of the fluorescent dye bis-carboxyethyl-carboxyfluorescein (BCECF). J Immunol Methods 108:255
21. Lindemann F, Schlimok G, Dirschedl P, Witte J, Riethmuller G (1992) Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients. Lancet 340:685
22. Moss TJ, Reynolds CP, Sather HN, Romansky SG, Hammond GD, Seeger RC (1991) Prognostic value of immunocytologic detection of bone marrow metastases in neuroblastoma. N Engl J Med 324:219
23. Rogge L, Barberis-Maino L, Biffi M, Passini N, Presky DH, Gubler U, Sinigaglia F (1997) Selective expression of an interleukin-12 receptor component by human T helper 1 cells. J Exp Med 185:825
24. Rogge L, Sinigaglia F (1997) Early events controlling T-helper cell differentiation: the role of the IL-12 receptor. Chem Immunol 68:38
25. Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA, White DE (1989) Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 210:474
26. Rosenberg SA, Spiess P, Lafreniere R (1986) A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233:1318
27. Scheicher C, Mehlig M, Dienes HP, Reske K (1995) Uptake of microparticle-adsorbed protein antigen by bone marrow-derived dendritic cells results in up-regulation of interleukin-1 alpha and interleukin-12 p40/p35 and triggers prolonged, efficient antigen presentation. Eur J Immunol 25:1566
28. Streilein JW, Grammer SF, Yoshikawa T, Demidem A, Vermeer M (1990) Functional dichotomy between Langerhans cells that present antigen to naive and to memory/effector T lymphocytes. Immunol Rev 117:159
29. Szabo SJ, Dighe AS, Gubler U, Murphy KM (1997) Regulation of the interleukin (IL)-12R beta 2 subunit expression in developing T helper 1 (Th1) and Th2 cells. J Exp Med 185:817
30. Topalian SL, Muul LM, Solomon D, Rosenberg SA (1987) Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J Immunol Methods 102:127
31. Topalian SL, Solomon D, Avis FP, Chang AE, Freerksen DL, Linehan WM, Lotze MT, Robertson CN, Seipp CA, Simon P (1988) Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J Clin Oncol 6:839
32. 51Cr-labeled targets for natural killer cytotoxicity assay. J Immunol Methods 122:15
33. Zeh HJ, III, Hurd S, Storkus WJ, Lotze MT (1993) Interleukin-12 promotes the proliferation and cytolytic maturation of immune effectors: implications for the immunotherapy of cancer. J Immunother 14:155